Use of the tumor necrosis factor-blockers for Crohn's disease

Table 18 Meta-analysis of efficacy and safety of biological therapies (26 wk to 60 wk) vs placebo in preventing relapse of disease activity in quiescent luminal Crohn's disease

Treatment	Outcome (RR in preventing relapse)
IFX, ADA, CER	RR = 0.71 (95%CI: 0.65-0.76, I2 = 5%, P = 0.38); NNT = 4 (95%CI: 3-5)
IFX, CER	Superior to PL
ADA	No statistically significant difference between ADA vs PL in preventing relapse
NAT (only one trial)	RR = 0.71; 95%CI: 0.61-0.84
Adverse events
Any event	RR = 0.93; 95%CI: 0.84–1.03
Infusion or injection site reactions	RR = 0.64; 95%CI: 0.06-6.66; (note that these reactions were actually fewer in those on anti-TNFα therapy, but the difference was not statistically significant)

PL: Placebo; CER: Certolizumab; IFX: Infliximab; ADA: Adalimumab; TNF: Tumor necrosis factor; RR: Risk ratio; CI: Confidence interval; NAT: Natalizumab.